Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Astera Labs, Inc.ALAB · Entity 1853 | Chief Financial Officer | February 17, 2026 | February 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Astera Labs, Inc.
Report date February 17, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 192,083 |
Ending reported balance
After 2026-02-17 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-02-17 · Sale · Disposed 753 · Balance 203,331 F1: Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $122.1000 to $122.2800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2026-02-17 · Sale · Disposed 4,250 · Balance 199,081 F1: Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $122.3200 to $123.3000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-02-17 · Sale · Disposed 3,556 · Balance 195,525 F1: Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $123.3300 to $124.3200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-02-17 · Sale · Disposed 2,281 · Balance 193,244 F1: Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $124.3500 to $125.3200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 5 · 2026-02-17 · Sale · Disposed 1,161 · Balance 192,083 F1: Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. |
| Common StockSEC Table I · non-derivative | IndirectBy Tate Trust | 450,281 |
Reported balance
Holding disclosure · report date 2026-02-17 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 450,281 F6: These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $122.1000 to $122.2800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $122.3200 to $123.3000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $123.3300 to $124.3200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $124.3500 to $125.3200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 04, 2024 Filed Dec 6, 2024 21:31 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 683 | $120.58 | $82,358.60 |
DisclosureSEC source: 0001736297-24-000067 · wk-form4_1733520683.xml · nonDerivative · entry 6 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 1,412,888 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $120.1800 to $121.1400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 21:31 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 4,353 | $119.67 | $520,922.20 |
DisclosureSEC source: 0001736297-24-000067 · wk-form4_1733520683.xml · nonDerivative · entry 5 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 1,413,571 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $119.1800 to $120.1400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 21:31 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 2,602 | $118.44 | $308,177.76 |
DisclosureSEC source: 0001736297-24-000067 · wk-form4_1733520683.xml · nonDerivative · entry 4 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 1,417,924 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $118.1500 to $119.0000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 21:31 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 2,840 | $117.68 | $334,221.71 |
DisclosureSEC source: 0001736297-24-000067 · wk-form4_1733520683.xml · nonDerivative · entry 3 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 1,420,526 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $117.1400 to $118.1100, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 21:31 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 1,900 | $116.66 | $221,657.04 |
DisclosureSEC source: 0001736297-24-000067 · wk-form4_1733520683.xml · nonDerivative · entry 2 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 1,423,366 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $116.0900 to $117.0000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 21:31 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 3,622 | $115.44 | $418,134.91 |
DisclosureSEC source: 0001736297-24-000067 · wk-form4_1733520683.xml · nonDerivative · entry 1 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 1,425,266 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $115.0900 to $116.0500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 22:44 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 1,599 | $117.10 | $187,242.90 |
DisclosureSEC source: 0001736297-24-000061 · wk-form4_1733352250.xml · nonDerivative · entry 16 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 1,428,888 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024. F18 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $117.0500 to $117.1700, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 22:44 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 23,222 | $116.46 | $2,704,394.64 |
DisclosureSEC source: 0001736297-24-000061 · wk-form4_1733352250.xml · nonDerivative · entry 15 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 1,430,487 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024. F17 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $116.0500 to $117.0400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 22:44 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 25,978 | $115.71 | $3,006,033.88 |
DisclosureSEC source: 0001736297-24-000061 · wk-form4_1733352250.xml · nonDerivative · entry 14 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 1,453,709 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024. F16 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $115.0500 to $116.0400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 22:44 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 19,804 | $114.54 | $2,268,314.51 |
DisclosureSEC source: 0001736297-24-000061 · wk-form4_1733352250.xml · nonDerivative · entry 13 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 1,479,687 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024. F15 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $114.0500 to $115.0400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 22:44 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 18,489 | $113.54 | $2,099,290.98 |
DisclosureSEC source: 0001736297-24-000061 · wk-form4_1733352250.xml · nonDerivative · entry 12 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 1,499,491 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024. F14 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $113.0300 to $114.0000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 22:44 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 27,905 | $112.53 | $3,140,250.11 |
DisclosureSEC source: 0001736297-24-000061 · wk-form4_1733352250.xml · nonDerivative · entry 11 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 1,517,980 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024. F13 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $112.0300 to $113.0200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 22:44 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 19,793 | $111.32 | $2,203,273.63 |
DisclosureSEC source: 0001736297-24-000061 · wk-form4_1733352250.xml · nonDerivative · entry 10 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 1,545,885 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024. F12 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.9700 to $111.9500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 22:44 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 21,670 | $110.52 | $2,395,072.42 |
DisclosureSEC source: 0001736297-24-000061 · wk-form4_1733352250.xml · nonDerivative · entry 9 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 1,565,678 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024. F11 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $109.9700 to $110.9650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 22:44 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 4,575 | $109.58 | $501,343.14 |
DisclosureSEC source: 0001736297-24-000061 · wk-form4_1733352250.xml · nonDerivative · entry 8 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 1,587,348 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $108.9500 to $109.9200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 22:44 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 1,180 | $108.16 | $127,626.79 |
DisclosureSEC source: 0001736297-24-000061 · wk-form4_1733352250.xml · nonDerivative · entry 7 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 1,591,923 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.8600 to $108.4600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 22:44 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 1,600 | $107.08 | $171,320.00 |
DisclosureSEC source: 0001736297-24-000061 · wk-form4_1733352250.xml · nonDerivative · entry 6 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 1,593,103 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $106.7900 to $107.5700, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 22:44 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 1,185 | $105.80 | $125,374.30 |
DisclosureSEC source: 0001736297-24-000061 · wk-form4_1733352250.xml · nonDerivative · entry 5 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 1,594,703 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $105.5800 to $106.4500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:44 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 3,700 | $104.44 | $386,429.48 |
DisclosureSEC source: 0001736297-24-000061 · wk-form4_1733352250.xml · nonDerivative · entry 4 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 1,595,888 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $104.0500 to $104.9100, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:44 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 84,220 | $103.49 | $8,715,919.38 |
DisclosureSEC source: 0001736297-24-000061 · wk-form4_1733352250.xml · nonDerivative · entry 3 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 1,599,588 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.0500 to $104.0300, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:44 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 55,003 | $102.59 | $5,642,576.26 |
DisclosureSEC source: 0001736297-24-000061 · wk-form4_1733352250.xml · nonDerivative · entry 2 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 1,683,808 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $102.0500 to $103.0400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:44 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 24,077 | $101.62 | $2,446,752.89 |
DisclosureSEC source: 0001736297-24-000061 · wk-form4_1733352250.xml · nonDerivative · entry 1 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 1,738,811 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $101.0500 to $102.0400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 22:29 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 7,398 | $90.81 | $671,833.83 |
DisclosureSEC source: 0001736297-24-000052 · wk-form4_1732141745.xml · nonDerivative · entry 1 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286,424 F1 · kind: Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.7000 to $91.0000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 14, 2024 Filed Nov 18, 2024 21:38 UTC | Astera Labs, Inc. ALAB · Entity 1853 | GrantCommon Stock | 694 | $30.60 | $21,236.40 |
DisclosureSEC source: 0001736297-24-000049 · wk-form4_1731965920.xml · nonDerivative · entry 1 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293,822 F1 · kind: These shares were acquired under the Astera Labs, Inc. 2024 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| October 09, 2024 Filed Oct 11, 2024 20:11 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 100,000 | $62.03 | $6,203,360.00 |
DisclosureSEC source: 0001736297-24-000036 · wk-form4_1728677459.xml · nonDerivative · entry 1 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Tate Trust Disclosed balance after: 1,762,888 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.0000 to $62.6300, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 20:03 UTC | Astera Labs, Inc. ALAB · Entity 1853 | GiftCommon Stock | 1,033,780 | $0.00 | $0.00 |
DisclosureSEC source: 0001736297-24-000035 · wk-form4_1728072185.xml · nonDerivative · entry 2 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 1,862,888 F1 · kind: On October 2, 2024, the Reporting Person transferred 1,033,780 shares of Common Stock to Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust") for no consideration. F2 · ownership.nature: These shares are owned directly by the Tate Trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 20:03 UTC | Astera Labs, Inc. ALAB · Entity 1853 | GiftCommon Stock | 1,033,780 | $0.00 | $0.00 |
DisclosureSEC source: 0001736297-24-000035 · wk-form4_1728072185.xml · nonDerivative · entry 1 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293,128 F1 · kind: On October 2, 2024, the Reporting Person transferred 1,033,780 shares of Common Stock to Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust") for no consideration. Read SEC document |
| August 29, 2024 Filed Sep 3, 2024 21:22 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 801 | $49.61 | $39,737.61 |
DisclosureSEC source: 0001736297-24-000028 · wk-form4_1725398539.xml · nonDerivative · entry 6 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 829,108 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on May 30, 2024. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.43 to $49.87. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 29, 2024 Filed Sep 3, 2024 21:22 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 9,967 | $48.74 | $485,791.58 |
DisclosureSEC source: 0001736297-24-000028 · wk-form4_1725398539.xml · nonDerivative · entry 5 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 829,909 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on May 30, 2024. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.37 to $49.29. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 29, 2024 Filed Sep 3, 2024 21:22 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 32,628 | $48.00 | $1,566,144.00 |
DisclosureSEC source: 0001736297-24-000028 · wk-form4_1725398539.xml · nonDerivative · entry 4 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 839,876 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on May 30, 2024. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.36 to $48.35. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 29, 2024 Filed Sep 3, 2024 21:22 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 5,204 | $46.95 | $244,327.80 |
DisclosureSEC source: 0001736297-24-000028 · wk-form4_1725398539.xml · nonDerivative · entry 3 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 872,504 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on May 30, 2024. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.36 to $47.34. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 29, 2024 Filed Sep 3, 2024 21:22 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 700 | $46.03 | $32,221.00 |
DisclosureSEC source: 0001736297-24-000028 · wk-form4_1725398539.xml · nonDerivative · entry 2 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 877,708 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on May 30, 2024. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.28 to $46.25. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 29, 2024 Filed Sep 3, 2024 21:22 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 700 | $44.26 | $30,982.00 |
DisclosureSEC source: 0001736297-24-000028 · wk-form4_1725398539.xml · nonDerivative · entry 1 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 878,408 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on May 30, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.94 to $44.74. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 20:03 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 13,915 | $41.79 | $581,507.85 |
DisclosureSEC source: 0001736297-24-000023 · wk-form4_1724184190.xml · nonDerivative · entry 1 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,326,908 F1 · kind: Represents shares of the Issuer's Common Stock sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sale is mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.78 to $41.86. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 20:20 UTC | Astera Labs, Inc. ALAB · Entity 1853 | GrantCommon Stock | 74,976 | $0.00 | $0.00 |
DisclosureSEC source: 0001736297-24-000021 · wk-form4_1723753220.xml · nonDerivative · entry 1 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,340,823 F1 · shares: These shares represent an award of restricted stock units ("RSUs") granted on August 13, 2024 (the "Grant Date") under the Astera Labs, Inc. Amended and Restated 2024 Stock Option and Incentive Plan. Such award which provides that the RSUs shall vest as to 25% on August 15, 2025 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 16, 2024 Filed May 20, 2024 21:42 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 4,125 | $76.40 | $315,150.00 |
DisclosureSEC source: 0001399546-24-000006 · wk-form4_1716241338.xml · nonDerivative · entry 2 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,265,847 F1 · kind: Represents shares of the Issuer's Common Stock sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sale is mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $76.33 to $76.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 16, 2024 Filed May 20, 2024 21:42 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 1,408 | $77.48 | $109,091.84 |
DisclosureSEC source: 0001399546-24-000006 · wk-form4_1716241338.xml · nonDerivative · entry 1 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,269,972 F1 · kind: Represents shares of the Issuer's Common Stock sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sale is mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $77.05 to $77.57. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 20:41 UTC | Astera Labs, Inc. ALAB · Entity 1853 | ConversionSeries A Preferred · Derivative | 879,108 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-035418 · ownership.xml · derivative · entry 3 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 0 Underlying: Common Stock · 879,108 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Preferred Stock automatically converted into one share of Common Stock on a one-for-one basis, immediately prior to the closing of the Issuer's initial public offering. The shares of Series A Preferred Stock have no expiration date. F2 · derivative.exercise_date: Each share of Series A Preferred Stock automatically converted into one share of Common Stock on a one-for-one basis, immediately prior to the closing of the Issuer's initial public offering. The shares of Series A Preferred Stock have no expiration date. F2 · derivative.expiration_date: Each share of Series A Preferred Stock automatically converted into one share of Common Stock on a one-for-one basis, immediately prior to the closing of the Issuer's initial public offering. The shares of Series A Preferred Stock have no expiration date. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 20:41 UTC | Astera Labs, Inc. ALAB · Entity 1853 | ConversionCommon Stock | 879,108 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-035418 · ownership.xml · nonDerivative · entry 2 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Tate Trust Disclosed balance after: 2,150,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of Series A Preferred Stock automatically converted into one share of Common Stock on a one-for-one basis, immediately prior to the closing of the Issuer's initial public offering. The shares of Series A Preferred Stock have no expiration date. F3 · ownership.nature: These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 20, 2024 Filed Mar 22, 2024 20:41 UTC | Astera Labs, Inc. ALAB · Entity 1853 | Tax withholdingCommon Stock | 28,689 | $36.00 | $1,032,804.00 |
DisclosureSEC source: 0000950170-24-035418 · ownership.xml · nonDerivative · entry 1 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,271,380 F1 · shares: Represents shares of Common Stock withheld by the Issuer in satisfaction of tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. Such withholding is mandated by an election of the Issuer made in advance and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 07, 2024 Filed Mar 21, 2024 20:27 UTC | Astera Labs, Inc. ALAB · Entity 1853 | GrantCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-034747 · ownership.xml · nonDerivative · entry 2 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,300,069 F1 · date: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F3 · shares: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F4 · shares: These shares represent an award of RSUs granted on February 7, 2024 under the 2018 Plan. Such award vests upon satisfaction of both (i) a time-based condition, which provides that 100% of the RSUs shall vest on February 15, 2025 and (ii) a performance-based condition, which is satisfied upon the occurrence of a change in control of the Issuer or the consummation of an initial public offering of the Issuer's equity securities, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. Read SEC document |
| January 24, 2024 Filed Mar 21, 2024 20:27 UTC | Astera Labs, Inc. ALAB · Entity 1853 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-034747 · ownership.xml · nonDerivative · entry 1 Tate Michael Truett · CIK 0001399546 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,262,569 F1 · date: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F2 · shares: These shares represent an award of restricted stock units ("RSUs") granted on January 24, 2024 under the Astera Labs, Inc. Amended and Restated 2018 Equity Incentive Plan ("2018 Plan"). Such award vests upon satisfaction of both (i) a time-based condition, which provides that the RSUs shall vest as to 25% on February 15, 2025 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter, and (ii) a performance-based condition, which is satisfied upon the occurrence of a change in control of the Issuer or the consummation of an initial public offering of the Issuer's equity securities, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. F3 · shares: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.